Results 201 to 210 of about 6,414,902 (294)

The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy. [PDF]

BMC Cancer
Wang JF, Cheng J.
europepmc   +1 more source

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Molecular minimal residual disease in resected non-small cell lung cancer: "flattening the curve". [PDF]

Transl Lung Cancer Res
Denis MG.
europepmc   +1 more source

Minimal residual disease in leukaemia and lymphoma

Annals of Oncology, 1990
F E, Cotter, C, Price, B D, Young, T A, Lister   +3 more
openaire   +2 more sources

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Provencio M, Serna-Blasco R, Nadal E, González Larriba JL, Martínez-Martí A, Bernabé Caro R, Bosch-Barrera J, Calvo V, Insa Molla A, Reguart N, de Castro Carpeño J, Aguado de la Rosa C, Palmero Sanchez R, Hernando Trancho F, Martín-López J, Rodríguez-Festa A, Mediavilla-Medel P, Lázaro M, Hayes J, Cruz-Bermúdez A, Massutí B, Romero A.   +21 more
europepmc   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors. [PDF]

Ther Adv Med Oncol
Nguyen T, Nguyen Hoang VA, Nguyen TH, Tran TH, Nguyen N, Le Vo TT, Nguyen DS, Giang H, Nguyen HN, Tu LN.   +9 more
europepmc   +1 more source

MagmaFlow: A desktop platform for artificial intelligence‐driven expression analysis

FEBS Open Bio, EarlyView.
MagmaFlow is a free, no‐code platform for gene expression analysis. It generates interactive volcano plots, links genes to literature, pathways, and diseases, prioritizes candidates using millions of publications, identifies affected biological processes, builds network diagrams, and exports publication‐ready figures and reports for macOS and Windows ...
Carlos E. Buss, Ao Li, Eduardo H. Gilglioni, Mayank Bansal, Sumeet Pal Singh, Latifa Bakiri, Alessandra K. Cardozo, Esteban N. Gurzov   +7 more
wiley   +1 more source

Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers. [PDF]

Int J Mol Sci
Putra AD, Darmawan NS, Rahman AT, Syariatin L.   +3 more
europepmc   +1 more source